| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | 0 |
Sells | $936,431 | 21 | 100 |
| Stuglik Brian M | director | 0 | $0 | 1 | $27,459 | $-27,459 |
| WILSON TROY EDWARD | director | 0 | $0 | 1 | $36,720 | $-36,720 |
| Ludwig Jeffrey Jerome | Chief Commercial Officer | 0 | $0 | 2 | $39,358 | $-39,358 |
| Dorval Allison | director | 0 | $0 | 1 | $39,474 | $-39,474 |
| Cesano Alessandra | director | 0 | $0 | 1 | $41,310 | $-41,310 |
| HUNT DOUGLAS M | See Remarks | 0 | $0 | 4 | $68,294 | $-68,294 |
| MOYES JAY M | director | 0 | $0 | 1 | $74,800 | $-74,800 |
| NOUGUES MAXIMO F | Chief Financial Officer | 0 | $0 | 4 | $81,263 | $-81,263 |
| MILLER MICHAEL PATRICK | director | 0 | $0 | 1 | $81,466 | $-81,466 |
| Senderowicz Adrian | director | 0 | $0 | 1 | $91,800 | $-91,800 |
| AUERBACH ALAN H | President and CEO | 0 | $0 | 4 | $354,487 | $-354,487 |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Over the last 12 months, insiders at Puma Biotechnology, Inc. have bought $0 and sold $936,431 worth of Puma Biotechnology, Inc. stock.
On average, over the past 5 years, insiders at Puma Biotechnology, Inc. have bought $0 and sold $1.07M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 56 shares for transaction amount of $4,619 was made by BRYCE RICHARD PAUL (SR VP, CLINICAL RESEARCH & DEV) on 2014‑04‑11.
| 2025-07-09 | Sale | AUERBACH ALAN H | President and CEO | 21,580 0.0427% | $3.54 | $76,285 | -2.40% | |
| 2025-07-09 | Sale | NOUGUES MAXIMO F | Chief Financial Officer | 3,935 0.0078% | $3.54 | $13,910 | -2.40% | |
| 2025-07-09 | Sale | HUNT DOUGLAS M | See Remarks | 3,443 0.0068% | $3.54 | $12,171 | -2.40% | |
| 2025-07-08 | Sale | AUERBACH ALAN H | President and CEO | 25,592 0.0507% | $3.53 | $90,417 | -1.20% | |
| 2025-07-08 | Sale | NOUGUES MAXIMO F | Chief Financial Officer | 5,587 0.0111% | $3.53 | $19,739 | -1.20% | |
| 2025-07-08 | Sale | HUNT DOUGLAS M | See Remarks | 4,374 0.0087% | $3.53 | $15,453 | -1.20% | |
| 2025-06-13 | Sale | Stuglik Brian M | director | 8,100 0.0165% | $3.39 | $27,459 | +2.54% | |
| 2025-06-13 | Sale | Dorval Allison | director | 11,610 0.0237% | $3.40 | $39,474 | +2.54% | |
| 2025-06-13 | Sale | Cesano Alessandra | director | 12,150 0.0248% | $3.40 | $41,310 | +2.54% | |
| 2025-06-13 | Sale | MOYES JAY M | director | 22,000 0.045% | $3.40 | $74,800 | +2.54% | |
| 2025-06-13 | Sale | WILSON TROY EDWARD | director | 10,800 0.0221% | $3.40 | $36,720 | +2.54% | |
| 2025-06-13 | Sale | Senderowicz Adrian | director | 27,000 0.0552% | $3.40 | $91,800 | +2.54% | |
| 2025-01-02 | Sale | AUERBACH ALAN H | President and CEO | 33,841 0.0696% | $3.15 | $106,657 | +0.80% | |
| 2025-01-02 | Sale | NOUGUES MAXIMO F | Chief Financial Officer | 10,227 0.021% | $3.15 | $32,232 | +0.80% | |
| 2025-01-02 | Sale | HUNT DOUGLAS M | See Remarks | 8,633 0.0178% | $3.15 | $27,209 | +0.80% | |
| 2025-01-02 | Sale | Ludwig Jeffrey Jerome | Chief Commercial Officer | 9,437 0.0194% | $3.15 | $29,743 | +0.80% | |
| 2024-08-12 | Sale | MILLER MICHAEL PATRICK | director | 23,358 0.0487% | $3.49 | $81,466 | -14.12% | |
| 2024-07-17 | Sale | AUERBACH ALAN H | President and CEO | 21,920 0.0461% | $3.70 | $81,128 | -17.53% | |
| 2024-07-17 | Sale | NOUGUES MAXIMO F | Chief Financial Officer | 4,156 0.0087% | $3.70 | $15,382 | -17.53% | |
| 2024-07-17 | Sale | HUNT DOUGLAS M | See Remarks | 3,637 0.0076% | $3.70 | $13,461 | -17.53% |
| AUERBACH ALAN H | President and CEO | 7180901 14.4665% | $24.77M | 0 | 62 | |
| NOUGUES MAXIMO F | Chief Financial Officer | 204229 0.4114% | $704,590.05 | 0 | 32 | |
| HUNT DOUGLAS M | See Remarks | 164894 0.3322% | $568,884.30 | 0 | 36 | |
| Ludwig Jeffrey Jerome | Chief Commercial Officer | 108951 0.2195% | $375,880.95 | 0 | 8 | |
| Stuglik Brian M | director | 94958 0.1913% | $327,605.10 | 0 | 4 | |
| Dorval Allison | director | 75390 0.1519% | $260,095.50 | 0 | 3 | |
| Cesano Alessandra | director | 68850 0.1387% | $237,532.50 | 0 | 1 | |
| MOYES JAY M | director | 53322 0.1074% | $183,960.90 | 0 | 7 | |
| MILLER MICHAEL PATRICK | director | 47000 0.0947% | $162,150.00 | 0 | 5 | |
| WILSON TROY EDWARD | director | 43550 0.0877% | $150,247.50 | 0 | 6 | |
| Senderowicz Adrian | director | 27000 0.0544% | $93,150.00 | 0 | 6 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 10 percent owner | 3696580 7.4471% | $12.75M | 21 | 9 | +98.94% |
| Malley Thomas | director | 156551 0.3154% | $540,100.95 | 4 | 0 | +51.73% |
| BRYCE RICHARD PAUL | SEE REMARKS | 121662 0.2451% | $419,733.90 | 2 | 39 | |
| Wong Alvin F | Chief Scientific Officer | 98214 0.1979% | $338,838.30 | 0 | 9 | |
| EYLER CHARLES R | SEE REMARKS | 31957 0.0644% | $110,251.65 | 0 | 10 | |
| CHARNAS ROBERT | 26453 0.0533% | $91,262.85 | 0 | 2 | ||
| Lo Steven | Chief Commercial Officer | 19557 0.0394% | $67,471.65 | 0 | 6 | |
| Miller Ann Calby | director | 12874 0.0259% | $44,415.30 | 0 | 1 |
$22,617,831 | 95 | 3.32% | $180.38M | |
$7,237,838 | 92 | -8.14% | $171.74M | |
$17,468,215 | 46 | 18.85% | $171.96M | |
$140,938,207 | 36 | 14.75% | $187.26M | |
$18,752,549 | 33 | -28.39% | $150.06M | |
$41,069,367 | 23 | 54.64% | $197.49M | |
$17,594,514 | 16 | -20.37% | $161.86M | |
$178,593,887 | 15 | -14.86% | $167.18M | |
$13,043,783 | 8 | 732.82% | $152M | |
$145,296,407 | 8 | -0.98% | $189.8M | |
Puma Biotechnology, Inc. (PBYI) | $17,675,244 | 7 | 92.20% | $171.25M |
$45,000,000 | 6 | -31.22% | $160.65M | |
$299,343 | 6 | -44.75% | $158.11M | |
$88,549,962 | 5 | -16.91% | $202.9M | |
$556,839 | 5 | 13.42% | $169M | |
$32,289,200 | 3 | -5.46% | $166.99M | |
$149,309 | 3 | 6.07% | $170.69M | |
$40,000,000 | 3 | -16.24% | $199.96M | |
$20,020,000 | 1 | -75.24% | $189.95M |
| Increased Positions | 69 | +63.3% | 3M | +10.13% |
| Decreased Positions | 43 | -39.45% | 2M | -6.82% |
| New Positions | 24 | New | 808,660 | New |
| Sold Out Positions | 19 | Sold Out | 563,560 | Sold Out |
| Total Postitions | 135 | +23.85% | 32M | +3.31% |
| Blackrock, Inc. | $12,350.00 | 7.7% | 3.85M | +23,563 | +0.62% | 2025-03-31 |
| Vanguard Group Inc | $11,695.00 | 7.29% | 3.64M | +7,231 | +0.2% | 2024-12-31 |
| Acorn Capital Advisors, Llc | $7,867.00 | 4.9% | 2.45M | +2M | New | 2024-12-31 |
| Acadian Asset Management Llc | $6,331.00 | 3.94% | 1.97M | +3,129 | +0.16% | 2024-12-31 |
| Millennium Management Llc | $6,080.00 | 3.79% | 1.89M | -986,762 | -34.25% | 2024-12-31 |
| Renaissance Technologies Llc | $5,635.00 | 3.51% | 1.76M | -16,900 | -0.95% | 2024-12-31 |
| Athyrium Capital Management, Lp | $4,033.00 | 2.51% | 1.26M | 0 | 0% | 2024-09-30 |
| Eversept Partners, Lp | $3,197.00 | 1.99% | 996,102 | -297,155 | -22.98% | 2024-12-31 |
| American Century Companies Inc | $3,044.00 | 1.9% | 948,376 | +73,833 | +8.44% | 2024-12-31 |
| Geode Capital Management, Llc | $2,951.00 | 1.84% | 919,435 | +2,068 | +0.23% | 2024-12-31 |